New England Journal of Medicine Archive — Page 2 of 5
-
October 24, 2022
Vanderbilt study finds that the most common oxygen saturation targets for hospitalized patients appear equally safe and effective
A Vanderbilt study looked at the oxygen saturation target that results in optimal outcomes — number of days alive and free of mechanical ventilation — in 2,500 critically ill adults receiving mechanical ventilation. -
July 6, 2022
Study shows two vaccine doses for mothers eases COVID complications for infants
Infants younger than 6 months were better protected from COVID-19 complications when mothers received two doses of the vaccine while pregnant, according to Vanderbilt researchers. -
June 8, 2022
Research probes cause of acute flaccid myelitis in children
Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM). -
May 12, 2022
VUMC-led study finds Moderna COVID vaccine safe and effective for children
-
May 10, 2022
New study illustrates how much it would cost for cancer drugs covered under Medicare Part D
A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit. -
December 8, 2021
International study supports dupilumab for treatment of moderate-to-severe asthma in children
In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients. -
May 20, 2021
VUMC is pacesetter for national aspirin study
According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.